FENC Company Profile and Key Details

Q: Who are the executives of FENC?

Ms. Ananya BhattacharyaHead of Medical Affairs & SafetyMr. Mark GowlandControllerMr. Rostislav RaykovChief Executive Officer & DirectorMs. Anne McKayRegulatory ConsultantMr. Robert C. AndradeChief Financial OfficerMr. Mark MeierSenior Vice President of CommercialMr. Adrian J. HaighChief Operating Officer

NASDAQ : FENC

Fennec Pharmaceuticals

$7.79

-0.07-0.89%

At Close 4:00 PM

64.34

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Fennec Pharmaceuticals Inc. (FENC) stock declined over -0.89%, trading at $7.79 on NASDAQ, down from the previous close of $7.86. The stock opened at $7.71, fluctuating between $7.67 and $7.90 in the recent session.

Stock Snapshot

7.86

Prev. Close

214.61M

Market Cap

7.67

Day Low

-29.96

P/E Ratio

-0.26

EPS (TTM)

-0.64

Cash Flow per Share

7.71

Open

27.55M

Number of Shares

7.9

Day High

74.74%

Free Float in %

-0.43

Book Value

86.11K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 10, 2026	7.71	7.90	7.67	7.79	86.46K
Feb 09, 2026	7.87	7.92	7.58	7.86	99.36K
Feb 06, 2026	7.75	7.95	7.55	7.84	91.32K
Feb 05, 2026	7.89	8.02	7.65	7.66	112.54K
Feb 04, 2026	7.97	8.10	7.74	7.94	139.08K
Feb 03, 2026	7.77	8.11	7.73	7.91	99.25K
Feb 02, 2026	7.53	7.93	7.40	7.83	133.94K
Jan 30, 2026	7.41	7.63	7.41	7.59	130.41K
Jan 29, 2026	7.51	7.60	7.37	7.52	99K
Jan 28, 2026	7.82	7.82	7.46	7.46	188.73K
Jan 27, 2026	7.69	7.95	7.68	7.85	95.07K
Jan 26, 2026	7.67	7.73	7.54	7.71	62.83K
Jan 23, 2026	7.76	7.76	7.65	7.66	56.61K
Jan 22, 2026	7.70	7.84	7.69	7.80	43.88K
Jan 21, 2026	7.40	7.70	7.40	7.70	87.24K
Jan 20, 2026	7.43	7.56	7.35	7.39	98.83K
Jan 16, 2026	7.46	7.63	7.35	7.59	93.53K
Jan 15, 2026	7.56	7.82	7.39	7.46	83.7K
Jan 14, 2026	7.55	7.67	7.40	7.58	398.59K
Jan 13, 2026	7.60	7.79	7.42	7.58	111.96K

Contact Details

Research Triangle Park, NC 27709

United States

https://www.fennecpharma.com 919 636 4530

About Company

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Stock Peers

ARGX

4.92+0.59%

argenx SE$833.16 REGN

-25.37-3.25%

Regeneron Pharmaceuticals, Inc.$754.91 MDGL

-9.43-1.93%

Madrigal Pharmaceuticals, Inc.$478.83 UTHR

0.08+0.02%

United Therapeutics Corporation$473.20 VRTX

-7.39-1.57%

Vertex Pharmaceuticals Incorporated$463.48 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

2.98+0.93%

Alnylam Pharmaceuticals, Inc.$322.98 PRAX

0.94+0.29%

Praxis Precision Medicines, Inc.$320.48 KRYS

-1.91-0.70%

Krystal Biotech, Inc.$270.70 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) closed at $7.79 USD, losing -$0.07 (-0.89%) from the previous close of $7.86. The stock is currently mid-range between its 52-week high and low $4.68 and $9.92. With a market capitalization of about $214.61 million, Fennec Pharmaceuticals Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.77). Key stats such as the average daily volume over the past year has been around 168.40 thousand shares, volume is running light vs its 52-week average. Headquartered in Research Triangle Park, NC, Fennec Pharmaceuticals Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jeffrey S. Hackman, the company employs approximately 32 people and listed since September 15, 2017. Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 1.35%, SMA50 1.55%, SMA200 -3.83%). The stock’s 14-day RSI is 51.92 (neutral), while the ATR of 0.33 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -21.47% below its high and over 66.45% above its low. Average 10-day trading volume of 108.85 thousand shares is below the 3-month average of 163.65 thousand, indicating normal recent market interest.

Valuation Metrics

Fennec Pharmaceuticals Inc. trades at a P/E ratio of -31.47, slightly below the S&P 500 average, with a price-to-sales ratio of 5.56 and a price-to-book ratio of -48.66 indicating negative book value, which may reflect financial stress. The P/FCF stands at -27.01, also below market averages.

Dividend & Fair Value

Fennec Pharmaceuticals Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$3.34. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Fennec Pharmaceuticals Inc. generated EPS of -$0.24 over the past year. Five-year average earnings growth is 52.21%. The latest quarter delivered EPS of -$0.02. The next quarter is forecast at $0.04. Next year's EPS is expected at $139.26. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $18.00 to $13.00. The high target offers 131.07% upside. The low target suggests 66.88% downside. The mean target is $14.20. This offers 82.28% upside. Fennec Pharmaceuticals Inc. earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by -75.0%. The prior quarter beat by 83.33%. Over the last six quarters, Apple has recorded several small beats. These include -433.33% in August 13, 2024.

Shareholding & Insider Activity

Fennec Pharmaceuticals Inc. has 27.83 million shares outstanding. The public float is 14.62 million shares, elevated short interest at 6.73% of float. This equals 1.28 million shares. The short ratio is 21.98 days. Institutional investors hold 69.11% of the float. Insiders own 16.25%. Essetifin SPA holds 3.99 million shares, Southpoint Capital Advisors LP has 2.74 million shares and MANCHESTER MANAGEMENT PR, LLC has 1.25 million shares. Over the past six months, insider transactions show net selling. They sold 1.39 million shares across 14 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Fennec Pharmaceuticals generated $21.64M in revenue, or $0.81 per share. Gross margin was 94.08%, operating margin -60.09%, and net profit margin -75.50%. Returns are negative, with ROA at -61.13% and ROE at 141.31%.
On valuation metrics, Fennec Pharmaceuticals trades at a P/E of -31.47, P/S of 5.56 and P/B of -48.66. The current ratio is 4.69 and quick ratio is 4.44. Operationally, the company’s inventory turnover is 1.08 and cash conversion cycle is -281.18 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is -4.03, supported by a cash flow-to-debt ratio of -0.44.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Fennec Pharmaceuticals posted revenue of $21.64M, down slightly from $1.54M in the prior quarter. Gross profit was $20.36M (margin 94.08%). Operating income was - $13.01M (margin -60.1%). Net income was- $16.34M (EPS - $0.61).
The company ended the quarter with $13.20M in cash and short-term investments, a total debt of $29.58M, and net debt of $16.38M. Total assets were $26.73M, with equity of - $11.56M. Financials further reflected weakness, with operating cash flow of - $17.46M, free cash flow of - $17.46M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Fennec Pharmaceuticals Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.93%, with price expected at $7.94 by February 24, 2026, within a range of $7.79 to $8.11 3-Month Outlook: Projected fall of -13.22%, reaching $6.76 by May 08, 2026, with a range of $6.63 to $6.89. 1-Year Outlook: Projected gain of 141.85%, with price at $18.84 by February 10, 2027, within a range of $6.49 to $29.98.

Key Takeaways

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) shares are flat -4.03% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Fennec Pharmaceuticals Inc. trading at a premium to the broader market with a P/E of -31.47. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $15.57, suggesting 99.87% upside. Our AI forecast model points to short-term strength (1.93% over two weeks), a medium-term fall (-13.22% over three months), and a longer-term gain (141.85% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Fennec Pharmaceuticals Inc. (FENC) stock price?

Fennec Pharmaceuticals Inc. (NASDAQ: FENC) stock price is $7.79 in the last trading session. During the trading session, FENC stock reached the peak price of $7.90 while $7.67 was the lowest point it dropped to. The percentage change in FENC stock occurred in the recent session was -0.89% while the dollar amount for the price change in FENC stock was - $0.07.

FENC's industry and sector of operation?

The NASDAQ listed FENC is part of Biotechnology industry that operates in the broader Healthcare sector. Fennec Pharmaceuticals Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of FENC?

Ms. Ananya Bhattacharya
Head of Medical Affairs & Safety
Mr. Mark Gowland
Controller
Mr. Rostislav Raykov
Chief Executive Officer & Director
Ms. Anne McKay
Regulatory Consultant
Mr. Robert C. Andrade
Chief Financial Officer
Mr. Mark Meier
Senior Vice President of Commercial
Mr. Adrian J. Haigh
Chief Operating Officer

How FENC did perform over past 52-week?

FENC's closing price is 66.45% higher than its 52-week low of $4.68 where as its distance from 52-week high of $9.92 is -21.47%.

How many employees does FENC have?

Number of FENC employees currently stands at 32.

Link for FENC official website?

Official Website of FENC is: https://www.fennecpharma.com

How do I contact FENC?

FENC could be contacted at phone 919 636 4530 and can also be accessed through its website. FENC operates from 68 TW Alexander Drive, Research Triangle Park, NC 27709, United States.

How many shares of FENC are traded daily?

FENC stock volume for the day was 86.11K shares. The average number of FENC shares traded daily for last 3 months was 168.4K.

What is the market cap of FENC currently?

The market value of FENC currently stands at $214.61M with its latest stock price at $7.79 and 27.55M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	32
Beta	0.77
Sales or Revenue	$21.64M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

FENC Company Profile and Key Details

Fennec Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Dividend & Fair Value

Company Overview

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Valuation Metrics